Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer

BACKGROUND: Endocrine therapies are the mainstay of treatment for oestrogen receptor (ER)-positive (ER(+)) breast cancer (BC). However, resistance remains problematic largely due to enhanced cross-talk between ER and growth factor pathways, circumventing the need for steroid hormones. Previously, we...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Breast Cancer Res
Autors principals: Ribas, Ricardo, Pancholi, Sunil, Rani, Aradhana, Schuster, Eugene, Guest, Stephanie K., Nikitorowicz-Buniak, Joanna, Simigdala, Nikiana, Thornhill, Allan, Avogadri-Connors, Francesca, Cutler, Richard E., Lalani, Alshad S., Dowsett, Mitch, Johnston, Stephen R., Martin, Lesley-Ann
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2018
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5992820/
https://ncbi.nlm.nih.gov/pubmed/29880014
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-018-0983-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars